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Survival of memory B lymphocytes is tightly linked to
the integrity of the Bcl-2 protein and is regulated by a
nerve growth factor (NGF) autocrine circuit. In factor-
starved memory B cells, the addition of exogenous NGF
promptly induced p38 mitogen-activated protein kinase
(MAPK), but not c-Jun N-terminal kinase (JNK), dephos-
phorylation. Conversely, withdrawal of endogenous
NGF was followed by p38 MAPK activation and translo-
cation onto mitochondria, whereby it combined with
and phosphorylated Bcl-2, as assessed by co-immuno-
precipitation and kinase assays in vivo and in vitro.
Mitochondria isolated from human memory B cells, then
exposed to recombinant p38 MAPK, released cyto-
chrome c, as did mitochondria from Bcl-2-negative
MDCK cells loaded with recombinant Bcl-2. Apoptosis
induced by NGF neutralization could be blocked by the
specific p38 MAPK inhibitor SB203580 or by Bcl-2 muta-
tions in Ser-87 or Thr-56. These data demonstrate that
the molecular mechanisms underlying the survival fac-
tor function of NGF critically rely upon the continuous
inactivation of p38 MAPK, a Bcl-2-modifying enzyme.
Apoptosis is a highly structured and ordered process that in
multicellular organisms eliminates superfluous, harmful, and
metabolically perturbed cells (1, 2). It can be triggered by
specialized surface receptor molecules, such as CD95 or TNFR,
or by stimuli as diverse as withdrawal of growth factors, expo-
sure to cell “poisons” (such as staurosporine or taxol), cortico-
steroids, viral infections, or even hypoxia. All of these signals
converge on the mitochondrial crossroads, whereby critical
events, such as cytochrome c efflux and formation of the apo-
ptosome, take place under the control exerted by proteins of the
Bcl-2 family (3–5).
It is established that the proapoptotic members of the family,
such as Bax, Bad, or Bag, form pores in the outer mitochondrial
membrane triggering cytochrome c release and that a subset of
the family, the so-called “BH3-only” proteins (Bid, Bim, Noxa,
Harakiri, etc.), enrolled in various cell types and metabolic
conditions, facilitate their oligomerization and membrane in-
sertion, initiating or augmenting their function (6). On the
other hand, the proposed mechanisms accounting for the func-
tion of the anti-apoptotic Bcl-2 proteins are diverse and some-
what less clear. In fact, Bcl-2 and Bcl-XL can either directly
combine with and inhibit the proapoptotic members or indi-
rectly modulate their activity by interfering with the mitochon-
drial membrane events they cause (4, 5). In parellel, a number
of studies have demonstrated that Bcl-2 and Bcl-XL can bind to
the mitochondrial proteins adenine nucleotide translocator (7)
and voltage-dependent anion channel (8, 9), suggesting that
their regulatory function can operate through the influence on
the gating properties of the latter, probably by keeping it in the
open configuration, thus allowing the exchange of metabolites
between cytosol and mitochondria (10). If so, structural modi-
fications affecting Bcl-2 or Bcl-XL might modify or even reverse
their antiapoptotic potential (11). In this connection, phospho-
rylation of Bcl-2 has been described to profoundly alter its
function, but contrasting reports have shown either loss (12–
17) or gain (18–22) of antiapoptotic properties after enzymatic
modification.
In multicellular organisms, the fate of a given cell is under
the social control exerted by the surrounding elements, which
deliver life or death signals. A class of molecular inputs that
keep alive the cell are the survival factors, whose surface re-
ceptors transmit signals that inhibit the pathways leading to
cell death. Nerve growth factor (NGF)1 is the first and perhaps
most representative protein of this class (23). Since NGF with-
drawal in factor-dependent cells typically affects Bcl-2 protein
(17, 24–27), we wanted to define the molecular events linking
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NGF surface receptors with Bcl-2 in memory B lymphocytes, a
cell type that depends on a functional NGF autocrine circuit for
survival (24). In the present paper, we describe that, upon
factor withdrawal, p38 mitogen-activated protein kinase
(MAPK) in its active form rapidly translocates onto mitochon-
dria, specifically interacts with Bcl-2, and phosphorylates it, an
event that is followed by cytochrome c release from the or-
ganelle and by apoptotic cell death. Transfection experiments
with Bcl-2 mutants bearing substitutions of Ser-87 or Thr-56
residues within the loop region showed increased resistance to
apoptosis induced by NGF withdrawal. The observation that
p38 MAPK is promptly dephosphorylated after NGF adminis-
tration to factor-starved cells indicates that the cytokine mod-
ulates the enzyme activation to maintain survival of NGF-de-
pendent cells.
EXPERIMENTAL PROCEDURES
Reagents—Neutralizing rat anti-human NGF mAbs (clone D11)
were kindly donated by Dr. A. Cattaneo (International School for Ad-
vanced Studies, Trieste, Italy), and always used at 10 g/ml. Rabbit
anti-human p38 MAPK, anti-human JNK, anti-human phosphorylated
JNK, anti-human actin, anti-human PARP, and goat and mouse anti-
human Bcl-2 Abs were purchased by Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Rabbit anti-human phosphorylated p38 MAPK was
purchased by New England Biolabs. Anti-human hsp60 was purchased
by Stressgen. Human recombinant active p38 MAPK-GST, JNK-GST,
and Bcl-2-GST were purchased by Upstate Biotechnology, Inc. (Lake
Placid, NY). HrATF2-GST was purchased by Santa Cruz Biotechnology.
Human recombinant NGF was a generous gift of Dr. G. Ferrari (Fidia,
Abano, Italy). The p38 MAPK inhibitor SB203580, the inactive
SB202474, the PD098059 MEK1/2 inhibitor, and the Trk-A inhibitor
K252a were purchased by Calbiochem. Anisomycin was purchased by
Sigma.
Human recombinant Bcl-2-His6-(1–218) was expressed with a C-
terminal His6 tag using pQE60 vector (Quiagen) in M15 cells (Esche-
richia coli). Recombinant protein was purified by resuspending 1-liter
cell cultures in 50 mM phosphate buffer, pH 8, with 300 mM NaCl, 10
mM imidazole. The cell suspension was incubated with 1 mg/ml ly-
sozyme for 30 min at 4 °C, sonicated to reduce viscosity, and centrifuged
at 10,000  g for 30 min. The supernatant was applied to a nickel-
activated Hi-TrapTM chelating column (Amersham Pharmacia Biotech)
and purified with an FPLC apparatus (Amersham Pharmacia), using a
wash step with 50 mM phosphate buffer, 300 mM NaCl, 30 mM imidaz-
ole, pH 8.0, until the A280 reached 0.01. Proteins were eluted with 250
mM imidazole, desalted against 10 mM Hepes, 150 mM NaCl, pH 7.4,
and stored at 20 °C.
Cell Isolation and Culture—Resting B lymphocytes were obtained
from human tonsils, and sIgD subpopulation were purified by panning
procedures using plastic Petri dishes coated with rabbit anti-human
IgD antibodies, as described (24). Cells were cultured in RPMI 1640
medium supplemented with 1% Nutridoma for immunoprecipitation
and Western blot analysis.
CESS and MDCK cell lines were purchased by ATCC (Manassas, VA)
and cultured in RPMI 1640 medium supplemented with 10% fetal calf
serum.
Phosphorylation Analysis of p38 MAPK and JNK—sIgD B cells
were cultured overnight at 2  105 cells/ml, washed, and incubated at
107 cells/ml with human recombinant NGF (100 ng/ml) or with 10 g/ml
anti-NGF Abs or rat IgG. At different time intervals, cells were washed,
lysed in sample buffer, run on SDS-PAGE, blotted onto nitrocellulose
filters, and stained with 0.1 g/ml rabbit anti-human phosphorylated
p38 MAPK or rabbit anti-human JNK. The reaction was visualized by
ECL detection system as recommended by the manufacturer (Amer-
sham Pharmacia Biotech). Membranes were stripped at 56 °C and
stained with 0.1 g/ml rabbit anti-human p38 MAPK or anti-human
JNK.
Immunofluorescence Analysis—For immunofluorescence analysis,
sIgD cells, treated with 10 g/ml anti-NGF Abs or control Ig for 4 h,
were incubated with 25 nM Mitotracker (Molecular Probes, Inc., Eu-
gene, OR) for 30 min at 37 °C and then attached on poly-L-lysine-
sensitized slides. The cells were fixed with 2% paraformaldheyde, per-
meabilized with 0.1% Triton X-100 in PBS, and, after saturation of
slides with 5% low fat dry milk (Bio-Rad) in phosphate buffer, stained
with 0.1 g/ml rabbit anti-human p38 MAPK, anti-human phosphoryl-
ated p38 MAPK, or preimmune rabbit IgG, followed by fluorescein
isothiocyanate-conjugated goat anti-rabbit IgG. The slides were ana-
lyzed by a confocal laser-scanning microscope.
Purification of Nuclear, Mitochondrial, and Cytosolic Fraction—108
cells were suspended in 5 mM Tris, pH 7.4, with 5 mM KCl, 1.5 mM
MgCl2, 0.1 mM EGTA, pH 8.0, containing 1 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, 5 g/ml aprotinin,
0.7 g/ml pepstatin for 30 min on ice, Dounce-homogenized, and cen-
trifuged at 750  g at 4 °C to obtain the nuclear fraction. The super-
natant was further centrifuged at 10,000  g for 30 min at 4 °C to
obtain the mitochondrial fraction (pellett) and the cytosolic fraction
(supernatant). For Western blot analysis, the nuclear and mitochon-
drial fractions were directly lysed in sample buffer, while the cytosolic
fraction was vacuum-concentrated and subsequently suspended in sam-
ple buffer. The purity of each fraction was assessed by staining aliquots
with Abs to hsp60 for mitochondria, to actin for cytosol, and to PARP for
nuclei.
Co-immunoprecipitation Studies—For co-immunoprecipitation stud-
ies, mitochondrial fraction from 108 sIgD cells, treated with 10 g/ml
anti-NGF antibodies or control IgG, were lysed in 10 mM Hepes, 142.5
mM KCl, 5 mM MgCl2, 1 mM EGTA, 0.2% Nonidet P-40, pH 7.5, and
immunoprecipitated with 1 g/ml rabbit anti-p38 MAPK Abs, anti-
Bcl-2 mAbs, or 1 g/ml polyclonal rabbit IgG or mouse IgG, followed by
protein A-Sepharose or protein G-Sepharose, respectively. The same
approach was used with recombinant proteins; a mixture of 200 ng of
rBcl-2-His6 and 200 ng of active rp38 MAPK-GST was immunoprecipi-
tated with 1 g/ml anti-Bcl-2, or with 1 g/ml rabbit anti-p38 MAPK
Abs or control Abs followed by protein G-Sepharose or protein A-Sepha-
rose. The immune complexes were washed, run on 10% SDS-PAGE, and
blotted onto nitrocellulose filter. 100 ng of human recombinant Bcl-2-
His or hrp38 MAPK-GST were used as internal standard.
Surface Plasmon Resonance Analysis—Surface plasmon resonance
analysis was performed using a BIACORE instrument with CM5 sensor
chips and an amine coupling kit (BIACORE AB). For immobilization of
proteins, the sensor chip was equilibrated with HBS buffer (10 mM
Hepes, 150 mM NaCl, 3.4 mM EDTA, pH 7.4, plus 0.005% p20 surfac-
tant) at 5 l/min and then activated by injecting 35 l of 0.2 M N-ethyl-
N-3-diethylaminopropylcarbodiimide, 0.05 M N-hydroxysuccinimide.
35 l of kinases or control protein at 20 g/ml in 10 mM sodium
acetate, pH 4.5, were then injected. Excess N-hydroxysuccinimide-es-
ters on the surface were deactivated with 35 l of 1 M ethanoldiamine-
hydrochloride (pH 8.5), and noncovalently bound dimers were washed
out with 10 l of regeneration buffer (4 M Gu-HCl buffered with 50 mM
phosphate buffer, pH 6.8). Binding experiments were performed with
10 mM Hepes, 150 mM NaCl, 20 mM MgCl2 as running buffer.
Phosphorylation Assays—For in vivo metabolic labeling, 107 sIgD
cells were incubated with 0.5 mCi of [32P]orthophosphate for 4 h in the
presence of 1 M okadaic acid or 10 l of ethanol vehicle control, in
phosphate-free medium, in the presence or absence of anti-NGF Abs, 25
M SB203580, SB202474, PD098059, or 100 ng/ml NGF. Cells were
then lysed as described, immunoprecipitated with anti-Bcl-2 Abs as
reported above, and separated on 10% SDS-PAGE. Gels were dried and
autoradiographed on Eastman Kodak Co. XAR films for 72 h at20 °C.
Kinase Assay—108 sIgD cells, treated with rat anti-NGF mAb for
12 h, were lysed in 20 mM Tris, pH 7.4, containing 1% Triton X-100, 10%
glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM -glycerophosphate, 2 mM
NaPP, 1 mM NaVO3, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml
leupeptin. 400 g of proteins were immunoprecipitated in duplicate
with 2 g/ml rabbit anti-p38 MAPK Abs coupled to Sepharose beads or
2 g/ml rabbit anti-JNK or with 2 g/ml control rabbit IgG. The efficacy
of immunoprecipitation was checked by Western blot analysis with
anti-P38 MAPK Ab or anti-JNK Ab. Immune complexes were incubated
with 0.25 g of human recombinant Bcl-2-GST protein or Bcl-2-His6 or
0.25 g of rATF-2-GST and 3 Ci of [32P]ATP (specific activity 3,000
Ci/mmol; Amersham Pharmacia Biotech), in the presence of 25 M
SB203580, or Me2SO as control, in 30 l of kinase buffer (25 mM Hepes,
pH 7.4, with 25 mM -glycerophosphate, 2 mM dithiothreitol, 0.1 mM
NaVO3). After 30 min at room temperature, samples were suspended in
2-ME sample buffer, run in SDS-PAGE, dried, and autoradiographed on
Kodak XAR films for 12 h at 20 °C. A kinase assay was performed in
the same experimental conditions by using 0.25 g of recombinant
active or inactive p38 MAPK-GST or JNK-GST and 0.25 g of
rBcl-2-His.
To assess the activity of recombinant proteins, 0.25 g of active rp38
MAPK or rJNK-GST were incubated, with or without 25 M SB203580,
with 0.25 g of rATF-2-GST in kinase buffer for 30 min in the presence
of 3 Ci of [-32P]ATP. Samples were run on SDS-PAGE and
autoradiographed.
Cytochrome c Release—Mitochondrial and cytosolic (S100) fractions
Bcl-2 Phosphorylation by p38 MAPK39028
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were prepared by resuspending cells (3 107) in 0.8 ml of mitochondrial
isolation buffer (250 mM sucrose, 20 mM Hepes, 10 mM KCl, 2 mM
MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride protease inhibitor, 2 g/ml leupeptin, 10 g/ml
aprotinin, pH 7.4). Cells were passed through an ice-cold cylinder cell
homogenizer. Unlysed cells and nuclei were pelleted via a 10-min,
750  g spin. The supernatant was spun at 10,000  g for 30 min at
4 °C, and the pellet containing the mitochondrial fraction was sus-
pended in modified mitochondrial isolation buffer with 75 mM MgCl2,
containing active p38 MAPK or active JNK (0.25 g), 200 M ATP, and
25 mM -glycerophosphate. After incubation at 30 °C for 30 min, the
mitochondrial mixture reactions were then centrifuged at 4,000  g for
10 min, and supernatant and pellet proteins were separated on SDS-
PAGE, followed by transfer to polyvinylidene difluoride membrane
(Amersham Pharmacia Biotech). The blot was probed with anti-human
cytochrome c peptide mAb (7H8.2C12, Pharmigen), diluted at 1:500. A
secondary probe (1:5,000 dilution) with horseradish peroxidase-labeled
antibodies (Amersham Pharmacia Biotech) was detected by ECL (Am-
ersham Pharmacia Biotech).
MDCK cells, detached by trypsin-EDTA, were washed twice in phos-
phate-buffered saline and suspended in 8 ml of mitochondrial isolation
buffer. Mitochondrial fractions were obtained as above and incubated
for 30 min on ice and 15 min at 22 °C, with or without extracts of E. coli
cells (8.5%, v/v), expressing Bcl-2-His6 or transformed with empty plas-
mid, obtained by lysing the cells with 20 mM Hepes, pH 7.4, 30 mM KCl,
1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin,
20 g/ml leupeptin, and 1% CHAPS. 0.25 g of active p38 MAPK or
JNK, with or without 25 M SB203580, was then added, and the
phosphorylation reaction was performed in the presence of 200 M ATP
(Amersham Pharmacia Biotech) for 30 min at 30 °C. Mitochondrial
mixture reactions were then centrifuged at 4,000  g for 10 min, and
then supernatant and pellet proteins were separated on SDS-PAGE,
blotted on polyvinylidene difluoride membranes, and stained with anti-
human cytochrome c mAbs.
Determination of PARP Cleavage, Annexin-V Staining, DNA Frag-
mentation, and Cell Viability—sIgD B cell subpopulations were cul-
tured at 5  106/ml, with 10 g/ml anti-NGF mAb or control rat IgG, in
the presence or absence of 25 M SB203580 for 12 h, lysed with 0.1%
Triton X-100 in PBS, run on SDS-PAGE, blotted onto nitrocellulose
filters, and stained with 1:1,000 anti-PARP mAbs, followed by peroxi-
dase-conjugated anti-mouse Abs. Reaction was visualized by ECL.
For annexin-V staining, the cells, cultured as above with anti-NGF
antibodies in the presence or absence of SB203580, were washed once in
PBS, incubated with 5 g/ml PE-annexin-V (Alexis) in binding buffer
(0.01 M Hepes, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM
CaCl2) for 15 min at room temperature. After washing, the cells were
analyzed by cytofluorimetry.
For DNA fragmentation analysis, sIgD, cultured at 5 106/ml, with
10 g/ml anti-NGF mAb or control rat IgG, in the presence or absence
of 25 M SB203580 for 12 h, were diluted 1:1.5 with 5 mM Tris, 20 mM
EDTA, and 0.5% (v/v) Triton X-100, pH 8.0, and allowed to lyse for 15
min on ice before centrifugation for 20 min at 27,000  g to separate
intact chromatin (pellet) from DNA fragments (supernatant). Pellets
were resuspended in 5 ml of a buffer containing 10 mM Tris and 1 mM
EDTA, pH 8.0, and pellet and supernatant samples were assayed for
DNA content, using the diphenylamine reagent (1.5% diphenylamine in
acetic acid plus 10% acetaldehyde) for 16 h at 30 °C. The optical density
at 600 nm was measured for each sample. Percentage of DNA fragmen-
tation was calculated as reported (24). Cell viability was evaluated by
trypan blue dye exclusion.
Construction of Bcl-2 Mutants—The full-length human-bcl-2 se-
quence was amplified by polymerase chain reaction from lysates of
freshly isolated human lymphocytes and cloned as a BglII/EcoRI frag-
ment in pIRES2-EGFP vector (CLONTECH), using the following prim-
ers 5-TTAGATCTATGGCGCACGCTGGGAGAAC-3 (forward) and 5-
CCGAATTCTCACTTGTGGCTCAGATAGG-3 (reverse), yielding the
wild type (WT) construct. To replace Thr-56, Ser-70, Thr-74, and Ser-87
with Ala, mutagenesis reactions using a QuikChangeTM site-directed
mutagenesis kit (Stratagene) were performed. The -loop plasmid,
containing the bcl-2 deletion mutant (40–91 amino acids), was genera-
ted by two-step recombinant polymerase chain reaction using WT as
template and two oligonucleotide pairs: 5 - CCACGGGCCCGGCGCC-
CACATCTCCCGC-3 with 5-GCAGAGCTGGTTTAGTGAACCGTC-
A-3 and 5-GGGCCCGTGGTCCACCTGGCCCTCCGCCAA- with 5-
TATTCCAAGCGGCTTCGGCCAGTAA-3.
The two polymerase chain reaction products were mixed in the same
polymerase chain reaction tube and reamplified with terminal primers.
The resulting deleted cDNA was purified, digested with BglII and
EcoRI restriction endonucleases, and ligated in the MCS of pIRES2-
EGFP. All constructs were verified by sequencing analysis.
Cell Culture, Transient Transfections, and Cytofluorimetric Analy-
sis—Transient transfections of CESS cells were obtained by Lipo-
fectAMINE (Life Technologies, Inc.). 2  106 cells were seeded into
six-well plates and incubated for 5 h in serum-free medium with 5 g of
test plasmid and lipids, according to the manufacturer’s instructions.
After 72 h, cells were washed and analyzed by using the FL-1 detector
of a FACScan flow cytometer (Becton Dickinson). For each sample, 104
cells were analyzed at a rate of 300 cells/s. The percentage of trans-
fected cells was calculated after subtracting the nonspecific fluores-
cence of nontransfected cells and resulted in 30%. Apoptotic stimuli
(10 g/ml of anti-NGF Abs for 12 h or 200 nM K252a for 6 h) were added
72 h after transfection, and GFP transfected cells undergoing apo-
ptosis were detected by PE-annexin-V staining and cytofluorimetric
analysis with both FL-1 and FL-2 detectors.
RESULTS
NGF Controls p38 MAPK Activation—In the NGF-respon-
sive cell line PC12, deprivation of NGF is followed by rapid
phosphorylation of two members of the MAPK family, p38 and
JNK (28–31). In order to assess these events also in memory B
lymphocytes, lysates from cells, initially starved (i.e. cultured
at low cellular density (12 h at 2  105/ml) to dilute the
autocrine factor) and then treated or not with exogenous NGF,
were analyzed in Western blots with anti-phosphorylated p38
MAPK or with anti-phosphorylated JNK Abs, which revealed
p38 MAPK activation in NGF-starved cells, rapidly declining
after NGF addition (Fig. 1A); in contrast, equal amounts of
phosphorylated JNK were observed under the same conditions
(Fig. 1A). These results suggested that in memory B cells p38
MAPK was specifically involved in the NGF signaling, the
difference between neural cells and memory B cells probably
residing in the expression of p38 MAPK-specific, but not JNK-
specific, phosphatase(s) in the latter cells, as described in other
systems (32).
Next, to characterize the molecular pathway comprising ac-
tivated p38 MAPK and antagonized by NGF, we checked
whether neutralization of endogenous NGF signaling with spe-
cific Abs (or with Trk-A inhibitor K252a, not shown) caused
enzyme hyperphosphorylation, which indeed occurred at early
times, as expected on the basis of similar results by others (28),
while the total amount of protein increased at later times (Fig.
1B). In contrast, JNK was not hyperphosphorylated in the
same experimental conditions (Fig. 1B).
Mitochondrial Localization of Activated p38 MAPK—p38
MAPK is a serine-threonine kinase, whose known molecular
targets are nuclear, such as ATF-2 or GADD153, or cytosolic,
such as hsp27, proteins (33). In the inactive state, its subcel-
lular location is the cytosol, from where it is translocated to the
nucleus, following metabolic activation (34). We next deter-
mined by immunofluorescence, using Abs specific for the acti-
vated form of p38 MAPK, the amount of memory B cells that
scored positive upon NGF neutralization, detecting 73  5% of
brightly staining cells, versus 7  2% in control cells, in three
independent experiments. During these studies we observed,
besides the nuclear staining, a spotted pattern of cytoplasmic
staining (within a diffuse cytosolic context), that suggested an
additional localization of the activated enzyme. Thus, to assess
in detail the physical translocation events of activated p38
MAPK, confocal laser-scanning microscopy experiments were
performed on memory B cells treated with anti-NGF or control
IgG and with Mitotracker (a rhodamine-like mitochondrial
dye) and then fixed and stained with p38 MAPK-specific Abs.
Fig. 2A shows that, after neutralization of endogenous NGF in
memory B cells, a definite mitochondrial focusing of p38 MAPK
from its cytosolic, diffuse location was evident, a localization of
the enzyme that was so far undetected. Staining with specific
Bcl-2 Phosphorylation by p38 MAPK 39029
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Abs revealed that essentially only the activated enzyme trans-
located to mitochondria (Fig. 2A).
Next, to confirm the above results, a biochemical analysis
was performed on mitochondrial, nuclear, and cytosolic frac-
tions from cells treated or not with anti-NGF Abs. Fig. 2B
shows that p38 MAPK was detected in cytosol and nuclei of
cells exposed to control Abs and that the enzyme also accumu-
lated in mitochondria of cells treated with anti-NGF Abs. In-
terestingly, when the same filters were stained with Abs
against the active form of p38 MAPK, specific bands were
evident in the mitochondrial and nuclear fractions and com-
pletely undetectable in the cytosolic fraction (Fig. 2C). Thus,
neutralization of NGF interaction with surface receptors was
reflected into activation of a serine/threonine-kinase, whose
mitochondrial localization opened the question regarding the
function exerted by the enzyme in that compartment.
p38 MAPK Binds Bcl-2—Several proteins, including en-
zymes, bind Bcl-2 (4) (e.g. the serine-kinase Raf-1, which
localizes in mitochondria of cells co-transfected with Bcl-2
and Raf-1 genes) (35, 36). We therefore wanted to ascertain
whether p38 MAPK was able to combine with Bcl-2. Mito-
chondria were purified from 108 memory B cells treated with
anti-NGF or control Abs, and either Bcl-2 or p38 MAPK was
immunoprecipitated, run in SDS-PAGE, and blotted onto
filters developed with anti-p38 MAPK or anti-Bcl-2 Abs, re-
spectively. Fig. 3A shows that p38 MAPK co-purified with
Bcl-2, particularly in cells exposed to anti-NGF Abs. The
presence of a variable number of apoptosizing cells at the end
of separation procedures accounts for the baseline amount of
p38 MAPK on mitochondria; a densitometric analysis of gels
from replicate experiments revealed a 62  18% increase of
p38 MAPK co-immunoprecipitated by anti-Bcl-2 Abs from
lysates of anti-NGF-treated cells (not shown). Fig. 3B shows
the reverse analysis, performed by immunoprecipitating p38
MAPK and revealing Bcl-2 co-purification. To ascertain
whether the two proteins interacted directly, without the
participation of adaptor or scaffold molecules, we performed
the same experiments using recombinant proteins only,
which showed that indeed this was the case (Fig. 3, C and D).
In all of the above experiments, specificity of immunoprecipi-
tation was assessed by staining the filters with the same Abs
used in the first step of the procedure, revealing that indeed
the Abs had recognized the nominal antigen.
Although Bcl-2 interacts with several molecular partners in
vivo (4), a quantitative assessment of its physical interaction
with a given protein is not available. In this connection, and to
gather further evidence of the ability of p38 MAPK and Bcl-2 to
combine, we set up experiments employing a biosensor-based
analysis, in which interaction of proteins, expressed in recom-
binant form, was monitored as a function of time (37). Fig. 3E
shows that Bcl-2 efficiently combined with p38 MAPK-GST
coupled to the solid phase (520 RU); in contrast, when JNK-
GST was tested under the same conditions, lower degrees of
interaction were detected (240 RU). The latter way of looking at
the interaction of different kinases with Bcl-2, namely in terms
of pure physical interaction, further confirms that p38 MAPK
combines with Bcl-2.
p38 MAPK Phosphorylates Bcl-2—The notion that Bcl-2 un-
dergoes phosphorylation on several serine and threonine resi-
dues within the loop between BH4 and BH3 domains (38),
which modifies its antiapoptotic potential (14, 17), raised the
question of whether the serine/threonine kinase p38 MAPK
could catalyze that reaction. To assess whether Bcl-2 phospho-
rylation by p38 MAPK occurred in cells deprived of NGF, 32PO4
autoradiography experiments were set up by immunoprecipi-
tating Bcl-2 from cells treated with either NGF or anti-NGF
Abs, in the presence or absence of SB203580 (a pyridyl-imida-
zole inhibitor of the enzyme (39)), of SB202474 (an inactive
pyridyl-imidazole compound (14)), and of PD098059 (a specific
MEK1/2 inhibitor (14)) as controls. Fig. 4A shows that phos-
phorylated Bcl-2 was recovered from anti-NGF-treated cells
but not from cells treated with NGF and that only the addition
of SB203580 inhibited phosphorylation. Again, specificity and
efficiency of Bcl-2 immunoprecipitation were assessed in par-
allel experiments run under the same experimental conditions
(Fig. 4A). These experiments were performed in the presence of
the phosphatase inhibitor okadaic acid; however, superimpos-
able results were obtained also in its absence (data not shown;
see Ref. 17). A similar approach with JNK, based on the reports
stating that also this enzyme can phosphorylate Bcl-2 (14,
40–44), could not be followed, because the described JNK in-
hibitors were unavailable to us. Thus, to confirm the above
findings in a cell-free system, p38 MAPK and JNK were puri-
fied from memory B cells exposed to anti-NGF Abs and tested
on recombinant Bcl-2 and ATF-2 proteins in the presence of
[32P]ATP. Fig. 4B shows that indeed the latter proteins became
phosphorylated after 30 min when exposed to p38 MAPK and
that the reaction was clearly modulated by SB203580. In con-
trast, no Bcl-2 and little ATF-2 phosphorylation was evident
upon exposure to purified JNK, consistent with the above de-
scribed evidence that NGF withdrawal failed to activate JNK
in the memory B cell system.
FIG. 1. NGF induces dephosphorylation of p38 MAPK, but not
of JNK. A, cell lysates from sIgD memory B cells, cultured with 100
ng/ml human recombinant NGF for the indicated times, were immuno-
blotted with 1 g/ml rabbit anti-human phosphorylated p38 MAPK or
rabbit anti-human phosphorylated JNK Abs. Restaining of membranes
with anti-actin Abs is also shown. Results of one representative exper-
iment out of three performed are shown. B, sIgD B cells were treated
for the indicated times with 10 g/ml rat anti-NGF mAb or control rat
IgG, lysed, and immunoblotted with rabbit anti-human phosphorylated
p38 MAPK Abs and then with anti-human p38 MAPK. sIgD B cells,
treated as above, were lysed and immunoblotted with anti-human phos-
phorylated JNK Abs and then with anti-human JNK. Results of one
experiment out of three performed are shown. Gel loading control,
performed by staining both membranes with anti-actin Abs, revealed
superimposable amounts of protein in each lane. C, sIgD cells were
stimulated with 10 g/ml anisomycin for 2 h, lysed, and immunoblotted
with anti-human phosphorylated JNK or anti-human phosphorylated
p38 MAPK.
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Finally, both p38 MAPK and JNK were obtained in recom-
binant form and tested in a Bcl-2 phosphorylation assay in the
presence of [32P]ATP, which again demonstrated that, under
the experimental conditions used, p38 MAPK, but not JNK,
was specifically active on Bcl-2 (Fig. 4C). In contrast, Fig. 4D
shows that both p38 MAPK and JNK preparations were active
on the common ATF-2 substrate and that SB203580 was able to
inhibit p38 MAPK activity only. Consistent results were ob-
tained when Bcl-2 phosphorylation by p38 MAPK (both in
recombinant form) was assessed in a BIAcore analysis, in that
FIG. 2. Neutralization of endoge-
nous NGF induces phosphorylation
and mitochondrial translocation of
p38 MAPK. A, immunofluorescence anal-
ysis of sIgD cells treated with 10 g/ml
anti-NGF Abs or control rat IgG for 4 h.
Cells were incubated with Mitotracker
and stained with rabbit anti-human p38
MAPK, rabbit anti-human phosphoryl-
ated p38 MAPK, or control rabbit IgG,
followed by fluorescein isothiocyanate-
conjugated goat anti-rabbit IgG. The
slides were analyzed by a confocal laser-
scanning microscope. Mitochondrial local-
ization of p38 MAPK, defined by yellow
spots indicating overlap of fluorescein and
rhodamine, was absent in samples of cells
treated with rat IgG. Staining of cells
with preimmune rabbit IgG did not show
detectable signal using a fluorescein filter
(not shown). Bar, 2 m. B and C, mito-
chondrial (M), nuclear (N), or cytosolic (C)
fractions of sIgD B cells, treated with 10
g/ml anti-NGF Abs or control IgG for
4 h, were blotted and stained with anti-
human p38 MAPK (B) or with anti-hu-
man phosphorylated p38 MAPK Abs (C).
All of the cellular fractions derived from
anti-NGF-treated cells contained p38
MAPK. In the same cells, the phosphoryl-
ated form of the enzyme localized on mi-
tochondria and was undetectable in the
cytosol. Densitometric analysis (mean 
S.D.) of active p38 MAPK in nuclei and
mitochondria from rat IgG-treated cells
(open bar) or anti-NGF-treated cells
(hatched bar) from five different experi-
ments are shown in the graph. Arbitrary
units are pixels/0.1 cm2. D, cytosolic, nu-
clear, and mitochondrial preparations
from cells treated with anti-NGF or con-
trol IgG were blotted and stained with
anti-hsp60, anti-human PARP, and anti-
actin Abs to assess the purity of subcellu-
lar fractions. For all of the panels, results
from one experiment out of five performed
are shown.
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anti-phosphoserine Abs, flowed through the reaction chamber
after removal of the enzyme, specifically recognized serine res-
idue(s) on immobilized Bcl-2 (not shown).2
On the whole, this set of experiments showed that Bcl-2
phosphorylation by activated p38 MAPK is a crucial event in
the metabolic cascade modulated by NGF in memory B cells.
Activated p38 MAPK Induces Cytochrome c Release from
Mitochondria and Apoptosis—The phosphorylation process in-
duces significant conformational changes, which may confer
diverse functional properties to proteins (45), and in fact phos-
phorylation of different members of the Bcl-2 family was shown
to increase or abolish their function (35, 46, 47). Bcl-2 phospho-
rylation was shown, in contrasting reports, to enhance or in-
hibit its antiapoptotic potential (12, 13, 15–22), in particular to
perturb specific functions, such as the control of cytochrome c
efflux from mitochondria (14). In our system, Bcl-2 phosphoryl-
ation was most likely related to the onset of apoptosis. To test
this hypothesis, mitochondria were isolated and incubated for
2 h with active p38 MAPK, and then the supernatants were
analyzed for the presence of cytochrome c. Fig. 5A shows that
the active form of p38 MAPK induced a dramatic release of
cytochrome c, which was specifically inhibited by SB203580.
When equal amounts of active JNK were tested, no cytochrome
c release was detected (Fig. 5A).
Next, to ascertain that cytochrome c release was uniquely
related to Bcl-2 phosphorylation, and not to modifications of
other companion proteins, experiments were performed on mi-
tochondria isolated from MDCK, a canine cell line that does not
express Bcl-2 (48). Recombinant Bcl-2 was added to mitochon-
dria and allowed to insert in the membrane, and then recom-
binant activated p38 MAPK or JNK were added, and the re-
lease of cytochrome c was assessed after 2 h. Fig. 5B shows that
only p38 MAPK, and not JNK, elicited cytochrome c release
and that again SB203580 was able to specifically inhibit the
phenomenon (by 68  3%, as assessed by densitometric anal-
ysis of gels from the three experiments performed). In partic-
ular, the addition of either enzyme to mitochondria not previ-
ously exposed to Bcl-2 failed to cause relase of cytochrome c,
indicating that they did not recognize any endogenous protein
involved in the translocation process.
The above experiments strongly suggested that Bcl-2 phos-
phorylation by p38 MAPK was causally related to cytochrome c
release. Consistently, it is remarkable that cleavage of PARP
(Fig. 5C) and the ensuing apoptosis of memory B cells (Fig. 5D),
both induced by NGF neutralization, could be prevented by
SB203580.
As a whole, these findings point to Bcl-2 phosphorylation by
p38 MAPK as the key event leading memory B cells to apo-
ptosis upon NGF deprivation.
Mutant Bcl-2 Proteins Inhibit Apoptotic Death after NGF
Withdrawal—We next wanted to extend the above observa-
tions, by assessing which serine and/or threonine residue of
Bcl-2 protein was involved in p38 MAPK-induced phosphoryl-
ation, by employing selected Bcl-2 mutants. Since resting cells
can be transfected with difficulty if at all, we used CESS cells,
2 G. De Chiara, M. E. Marcocci, F. Pichiorri, M. Lucibello, A. L. Rosa,
P. Rosini, A. T. Palamara, E. Garaci, M. Torcia, and F. Cozzolino,
manuscript in preparation.
FIG. 3. Bcl-2 and p38 MAPK interaction. A, mitochondrial fractions, obtained from 108 sIgD B cells, treated with 10 g/ml anti-NGF Abs
or control IgG for 4 h, were lysed and immunoprecipitated (IP) with anti-human Bcl-2 Abs (lanes 1 and 2) or with control mouse Ig (lanes 3 and
4), run on SDS-PAGE (control IgG-treated cells (lanes 1 and 3) and anti-NGF-treated cells (lanes 2 and 4)), blotted, and stained with anti-human
p38 MAPK Abs. The same nitrocellulose filter was stripped and restained with anti-human Bcl-2 Abs. Results of one experiment out of four
performed are shown. B, mitochondrial fractions of 108 sIgD B cells, treated as in A, were immunoprecipitated with anti-human p38 MAPK Abs
(lanes 1 and 2) or rabbit Ig (lanes 3 and 4) and stained with anti-human Bcl-2 Abs (control IgG-treated cells (lanes 1 and 3) and anti-NGF-treated
cells (lanes 2 and 4)). The same nitrocellulose filter was stripped and restained with anti-human p38 MAPK Abs. The results of one experiment
out of four performed are shown. C, a mixture of rBcl-2-His6 (250 ng) and active rp38 MAPK-GST (250 ng) was immunoprecipitated with anti-Bcl-2
(lane 1) or control Abs (lane 2). The immune complexes were stained with anti-p38 MAPK Abs. Lane 3, rp38 MAPK (internal standard). The same
nitrocellulose filter was stripped and restained with anti-human Bcl-2 Abs. Results of one experiment out of three performed are shown. D, a
mixture of rBcl-2-His6 (250 ng) and active rp38 MAPK-GST (250 ng) was immunoprecipitated with anti-p38 MAPK (lane 1) or control Abs (lane
2). The immune complexes were stained with anti-human Bcl-2 Abs. Lane 3, rBcl-2-His6 (internal standard). The same nitrocellulose filter was
stripped and restained with anti-human p38 MAPK Abs. Results of one experiment out of three performed are shown. E, overlay plot of
sensorgrams obtained with Bcl-2-His6 over chips containing immobilized active p38 MAPK-GST, active JNK-GST, or GST. The bindings recorded
were 520 RU for active p38 MAPK-GST, 240 RU for active JNK-GST, and 90 RU for GST.
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which bear a sIgG phenotype, produce NGF, and express NGF
receptors, thus presenting biochemical features similar to
those of memory B cells (17). We cloned WT Bcl-2 and a series
of mutants, in which either the coding sequence for the entire
loop region of the molecule was deleted (-loop) or Thr-56,
Ser-70, Thr-74, or Ser-87 was replaced by Ala in plasmids
coding for green fluorescent protein (GFP) as reporter. CESS
cells were transfected with the above constructs or with a void
plasmid, and apoptosis (revealed by cytofluorimetric analysis of
annexin-V staining) was recorded after exposure to anti-NGF
Abs. Although a significant level of protection from apoptosis
was achieved in cells transfected with WT plasmid, as com-
pared with native CESS cells or to mock-transfected cells, the
-loop mutant presented strong resistance to NGF withdrawal
(Fig. 6). When point mutants were tested, we observed that
T56A and S87A mutants showed levels of resistance to apo-
ptosis comparable with those of -loop mutant, while T74A and
S70A mutants did not (Fig. 6); superimposable results were
obtained by inducing apoptosis with K252a compound (not
shown). The latter findings strongly indicate that phosphoryl-
ation of Thr-56 and/or Ser-87 is causally linked to apoptosis
induced by withdrawal of NGF in sIgD B cells.
DISCUSSION
NGF is a classical survival factor, essential for a large num-
ber of cell types, including neurons, keratinocytes, and memory
B lymphocytes (24–27). In all of these cells, discontinuation of
the NGF signal invariably causes apoptotic cell death that
critically involves mitochondria with alterations of proteins of
the Bcl-2 family, as occurs in different systems after the re-
moval of other survival factors (49). How withdrawal of such
factors, particularly of NGF, reverberates onto mitochondria is
not completely defined. Our observations delineate a pathway
that relays the extracellular signal of NGF or its absence with
the maintenance or alteration of Bcl-2 integrity and may there-
fore be useful for understanding the vertical connections be-
tween cell surface and the mitochondrial phase of apoptosis.
We observed that, upon NGF signaling in memory B cells,
p38 MAPK was dephosphorylated, while the addition of neu-
tralizing anti-NGF Abs caused its phosphorylation and trans-
location to mitochondria. This alternative localization of the
activated enzyme, so far undescribed, may be related to the
phosphorylation status of paxillin, a focal adhesion protein
involved in linking actin filaments to the plasma membrane
(50), is analogous to the reported translocation of JNK to the
same compartment (51), and appears to be dictated by its
affinity for Bcl-2, as revealed by the co-localization experi-
ments, the co-immunoprecipitation studies, and the biosensor
analysis. Translocation of p38 MAPK to the mitochondrial com-
partment was also functionally meaningful, as suggested by
the ample evidence that the enzyme, in native or recombinant
form, can phosphorylate Bcl-2, its activity being specifically
counteracted by the inhibitor SB203580 or by the deletion of
the Bcl-2 loop region (17). Following Bcl-2 phosphorylation,
cytochrome c outpouring, activation of caspase-3-like enzymes
(as shown by PARP cleavage), externalization of phosphatidyl-
serine, and DNA degradation occurred in cells treated with
anti-NGF Abs, events that could be prevented by SB203580 or
by mutations of selected residues of Bcl-2 protein. A final piece
of evidence comes from the recent observation made in our
laboratory that Bcl-2 phosphorylation does not occur in fibro-
blasts from p38 MAPK/ embryos (52) under serum with-
drawal conditions leading to Bcl-2 phosphorylation in control
p38 MAPK/ fibroblasts.2 On this basis, we suggest that a
major biochemical link between NGF receptors and the mito-
chondrial compartment is p38 MAPK, whose function is there-
fore critical for apoptosis of memory B cells and, possibly, of the
other cell types that rely solely on Bcl-2 for survival, as further
discussed below.
It is believed that the antiapoptotic properties of Bcl-2 and
Bcl-XL rely on the ability of native molecules to bind a number
of proapoptotic members of the family, such as Bad, Bim,
Harakiri, Bik, and, possibly, also Bax (6), preventing or inhib-
FIG. 4. Bcl-2 is phosphorylated by p38 MAPK. A, 32PO4 metabolic
labeling of sIgD B cells treated for 4 h with 10 g/ml control Ig or
anti-NGF Abs, with anti-NGF Abs plus 25 M SB203580, 25 M
SB202474, 25 M PD098059, or with 200 ng of NGF. Cell lysates were
immunoprecipitated with anti-Bcl-2 Abs and run on 10% SDS-PAGE.
Duplicate gels were dried and autoradiographed (upper panel) or blot-
ted onto nitrocellulose filters and stained with anti-Bcl-2 Abs (lower
panel). Results from one experiment out of six performed are shown. B,
in vitro kinase assay of immunopurified p38 MAPK or immunopurified
JNK from lysates of anti-NGF-treated IgD B cells. Immunopurified
p38 MAPK, JNK, or control IgG-immunoprecipitated proteins were
incubated, in the presence of [-32P]ATP, with 250 ng of rBcl-2-His6,
rBcl-2-His6 plus 25 M SB203580, or rBcl-2-His6 plus Me2SO (DMSO)
as control vehicle. The immunopurified proteins were incubated, in the
same experimental conditions, with rATF-2-GST (250 ng). The reac-
tions were stopped after 30 min, and the samples were run on SDS-
PAGE, dried, and autoradiographed. Immunopurified p38 MAPK phos-
phorylates Bcl-2 and ATF-2-GST, while immunopurified JNK does not.
Results from one experiment out of three performed are shown. The
efficacy of immunoprecipitation was checked by running duplicate im-
munoprecipitation (IP) samples in separate gels and by staining the
membranes with anti-human p38 MAPK or anti-human JNK. C, active
rp38 MAPK-GST or active rJNK-GST were incubated with rBcl-2-His6
(250 ng) in the presence of [-32P]ATP. Samples were run on SDS-PAGE
and autoradiographed. rBcl-2 was phosphorylated by rp38 MAPK-GST,
and the reaction was specifically inhibited by SB203580. Results from
one experiment out of three performed are shown. D, active rp38
MAPK-GST or rJNK-GST were incubated, in the presence or absence of
25 M SB203580, with rATF-2-GST (250 ng) in the presence of
[-32P]ATP. Samples were run on SDS-PAGE and autoradiographed.
rATF-2-GST was phosphorylated by either kinase, but SB203580 spe-
cifically inhibited rp38 MAPK-GST only. Results from one experiment
out of three performed are shown.
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iting their functions. Moreover, Bcl-2 and Bcl-XL interact with
proteins making up the permeability transition pore complex,
particularly VDAC and ANT (7–10, 53), and cooperate in main-
taining these molecules in a physiological state. However,
when the BH4 domain is removed (11, 54), their properties may
switch toward promotion of apoptosis (55). Our data suggest
that even more limited modifications, such as phosphorylation,
can alter Bcl-2 function, leading to a proapoptotic molecule. In
fact, Bcl-2 phosphorylation may act either disrupting the inter-
molecular cooperation (12, 15, 53) or rendering the protein
susceptible to proteolytic enzymes (56). While a number of
reports are consistent with our contention (12–14, 16, 17),
others reach the opposite conclusion (18–20), suggesting that
Bcl-2 has to be phosphorylated in order to act as an antiapo-
ptotic factor. Bcl-2 protein has several residues potentially
targeted by serine/threonine kinases in the loop region and
linked to apoptosis, as reported by others (14, 38, 57). Our
observation that single substitutions of Bcl-2 threonine 56 or
serine 87 with alanine caused reduced sensitivity to NGF neu-
tralization strongly indicates that these residues, once targeted
by p38 MAPK, trigger cell death. This finding, taken together
with the notion that a phosphorylated serine 70 is needed to
ensure cell survival after etoposide treatment (18), suggests
that a precise combination of activated and deactivated resi-
dues dictates the shaping of Bcl-2 folding that governs its
gating functions. Deciphering the combination, a task cur-
rently under way in our laboratory, should solve the inconsis-
tencies regarding phosphorylation of Bcl-2 protein and its func-
tion in the apoptotic process.
We observed that JNK, another member of the MAPK/stress-
activated protein kinase family, was not deactivated upon NGF
signaling. This finding is in partial accordance with the find-
ings of Kummer et al. (28), who had shown that the enzymatic
activities of both JNK and p38 MAPK diminished after admin-
istration of NGF to PC12 cells. This difference might be ex-
plained by the absence, at this stage of lymphoid maturation, of
the enzymatic machinery needed to dephosphorylate JNK upon
NGF addition, as occurs to p38 MAPK, since specific phos-
phatases are involved in the inactivation of the two kinases
(32). However, it is also possible that the two members of the
MAPK family, JNK and p38, preferentially interact with
Bcl-XL and Bcl-2, respectively, as suggested by the recent dem-
onstration that JNK specifically phosphorylates Thr-47 and
Thr-115 residues in Bcl-XL protein (51); if so, since memory B
cells do not express Bcl-XL (58), the absence of the natural
mitochondrial target of JNK would render dispensable the
specific cytosolic phosphatase instead needed in PC12 cells that
express both Bcl-2 and Bcl-XL. Consistent with the hypothesis
of preferential interactions of kinases, although JNK was re-
ported to bind and phosphorylate Bcl-2 in cell transfection
assays (14, 41), we observed a limited degree of JNK/Bcl-2
interaction in a biosensor analysis. Moreover, in our system,
FIG. 5. p38 MAPK induces release of cytochrome c from mitochondria and SB203580 prevents apoptosis. A, mitochondria isolated
from sIgD B cells were incubated for 2 h with 250 ng of active rp38 MAPK, with active rp38 MAPK in the presence of 25 M SB203580, or with
250 ng of active rJNK. Reaction supernatants and mitochondrial lysates were immunoblotted with anti-cytochrome c Abs. Results from one
experiment out of three performed are shown. B, mitochondria isolated from MDCK cells were incubated with lysates of E. coli cells expressing
Bcl-2-His6 or transformed with empty vectors, in the presence of ATP and active rp38 MAPK, active rp38 MAPK plus SB 203580, or active rJNK.
Supernatants of reaction mixtures and mitochondrial lysates were run on SDS-PAGE, blotted, and stained with anti-cytochrome c Abs. The lower
gel shows the mitochondrial extracts immunoblotted with anti-Bcl-2 Abs to ascertain that the recombinant protein had inserted into the organelle
membranes. Results from one experiment out of three performed are shown. C, cell lysates from sIgD B cells, incubated with 10 g/ml rat IgG,
anti-NGF Abs, anti-NGF Abs plus 25 M SB203580, or with Me2SO (DMSO) as control vehicle, were immunoblotted with anti-PARP Abs. PARP
cleavage, induced by anti-NGF Abs, was inhibited by SB203580. Results from one experiment out of three performed are shown. D, sIgD B cells
were cultured with anti-NGF Abs or control IgG, in the presence or absence of SB203580. Both DNA fragmentation (detected at the indicated times
by diphenylamine method) and phosphatidylserine surface expression (detected by PE-conjugated annexin-V staining and fluorescence-activated
cell sorting analysis) were induced by anti-NGF Abs and inhibited by SB203580. Results from one experiment out of three performed are shown.
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JNK failed to phosphorylate recombinant Bcl-2, and the addi-
tion of activated JNK to mitochondria loaded with Bcl-2 did not
elicit cytochrome c release, while both phosphorylation of Bcl-2
and the subsequent cell death were blocked by the p38 MAPK
inhibitor we used. Although the SB compound was shown to
affect also the RAF-1 kinase, paradoxically in a stimulant
fashion, leaving the possibility that in our system other en-
zymes may be involved (64), the latter data, taken together
with the above considerations, strongly indicate that in mem-
ory B cells the axis NGF receptor-p38 MAPK-Bcl-2 is the major
regulator of the death/survival divide.
At present, the phosphatase(s) deactivating p38 MAPK upon
NGF receptor signaling is unknown. Instead, recent work has
provided hints to understand the trigger initiating the MAPK-
activating pathway that leads to p38 MAPK phosphorylation in
the absence of NGF. The notion that the p75NTR receptor chain
can induce cell death in the absence of its ligands (59) and the
demonstration that neurons of transgenic mice expressing a
truncated form of p75NTR undergo accelerated apoptosis (60)
had pointed to that molecule as the initiator of the process,
consistent with our observation that neutralization of either
NGF receptor chain causes memory B cell death.3 Recently, it
has been shown that the intracellular portion of p75NTR can
bind adaptor molecules, such as TRAF2, when the molecule is
in monomeric form (i.e. in the absence of extracellular NGF),
whereas it binds TRAF6 when dimerized via the extracellular
bridging of NGF (61, 62). While oligomerized TRAF6 leads to
the nuclear translocation of NF-B (62), TRAF2 is able to
trigger the MAPK pathway down to p38 MAPK activation (63).
On the contrary, it is conceivable that, when the ligand-binding
extracellular region is occupied by NGF, the intracellular por-
tion of p75NTR binds, directly or indirectly, a p38 MAPK-spe-
cific phosphatase (possibly activated upon phosphorylation by
Trk), a hypothesis currently being tested in our laboratory.
Our studies were performed essentially on freshly isolated,
normal memory B cells, reflecting naturally occurring molecu-
lar events, and it is remarkable that the alternative localiza-
tion of activated p38 MAPK on mitochondria can be observed
shortly after a simple exposure of normal cells to neutralizing
anti-NGF Abs. On the whole, by delineating the vertical con-
nections between a cell surface signal and mitochondria, where
the post-translational modifications of Bcl-2 affecting its anti-
apoptotic properties occur, the present data provide informa-
tion that may be helpful in designing pharmacological strate-
gies to influence the survival of memory B cells and probably of
other different cell types.
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